+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07507318

Phase 2 Study of Oral Chidamide Maintenance for Adults with Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma in Complete Response but ctDNA MRD-Positive

Led by Rong Tao · Updated on 2026-06-18

69

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the use of chidamide as a maintenance treatment for adults with newly diagnosed double-expressor diffuse large B-cell lymphoma DLBCL who have achieved complete response after induction therapy but still show minimal residual disease MRD detected by circulating tumor DNA ctDNA. This phase 2, prospective, multicenter, single-arm, open-label study focuses on patients at high risk of relapse despite initial success, as identified by persistent molecular disease. Chidamide is an oral drug that may have antitumor and immune-modulating effects in B-cell lymphomas. Participants will receive oral chidamide 20 mg on Days 1, 4, 8, and 11 of each 21-day cycle. ctDNA MRD will be tested every 12 weeks to monitor disease status. Treatment will continue until participants have two consecutive MRD-negative results at least 3 months apart, experience disease progression, encounter intolerable side effects, withdraw consent, or complete 2 years of maintenance therapy. This study does not include a control group and focuses on the single intervention of chidamide maintenance. During the study, participants will have regular assessments including ctDNA MRD testing every 12 weeks. Researchers will measure the rate of MRD negativity and progression-free survival at 2 years as main outcomes, along with event-free survival, overall survival, and safety. The study will monitor treatment-emergent adverse events up to 30 days after the last dose. Participants may stay in the trial for up to 2 years, with ongoing safety and efficacy evaluations throughout this period.

CONDITIONS

Brief Title

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Research Team

R

Rong Tao, MD & PhD

W

Wenhao Zhang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here